Key Takeaways The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...

Eli Lilly's operational performance is strong ... shares have seen downside of 14.8% at a time when the S&P 500 is up 2.6%. The picture isn't as bad when we compare the data to my original ...

Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential ...

Eli Lilly (NYSE:LLY) shares continued to soar this year with a YTD gain of ~34% compared to a ~25% rise in the S&P 500 (SP500), while Novo (NVO) has lost ~16%. In fact, the Indiana-based drugmaker ...

The sector has lagged the overall market's rally this year, up just 1.1%, while the S&P 500 has surged 26.2% ... Novo Nordisk and Zepbound maker Eli Lilly. The selloffs "reflect more fear than ...

S&P 500 edges higher, Nasdaq dips in choppy session as inflation data eyed 12:08 AM UTC Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...